Considerations in the management of younger patients with colorectal cancer.
Journal
Clinical advances in hematology & oncology : H&O
ISSN: 1543-0790
Titre abrégé: Clin Adv Hematol Oncol
Pays: United States
ID NLM: 101167661
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
entrez:
15
3
2022
pubmed:
16
3
2022
medline:
18
3
2022
Statut:
ppublish
Résumé
The incidence of colorectal cancer in patients ages 18 to 49 years has increased by 51% throughout the past 3 decades. In the United States, recent guidelines lowered the initial screening age to 45 years. More than 75% of colorectal tumors in younger patients are diagnosed based on the onset of symptoms, such as rectal bleeding, abdominal pain, weight loss, or anemia. In most cases, these individuals do not have a family history of colorectal cancer. On average, the diagnosis of colorectal cancer in younger patients occurs from 6 months to several years after symptoms first arise. As a result, younger patients diagnosed with colorectal cancer tend to present with advanced disease. If a younger patient does not have any contraindications, it is appropriate to consider treatment with a triplet chemotherapy combined with a biologic. The impact of treatment can be greater for younger patients than for older individuals. Even mild or moderate toxicities can strongly impact their daily lives. Younger patients with colorectal cancer are likely to have a higher risk for long-term treatment-related sequelae, particularly because they tend to present with advanced disease and will receive therapy for a prolonged period.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM